Chi Yan

By Kensey Bergdorf Ann Richmond In a continuation of previous work studying the role of chemokine receptor CXCR2 in immune cells published in Cancer Immunology Research, the lab of Ann Richmond, Ingram Professor of Cancer Biology and professor of pharmacology, has identified that same receptor as a regulator of melanoma… Read More

L-R: Ann Richmond, Chi Yan By Wendy Bindeman Ann Richmond, professor of pharmacology, and Chi Yan, a research assistant professor in the Richmond lab, recently published a study showing that expression of a protein called CD40 can be used to predict response to immunotherapy in malignant melanoma. Read More

Many melanoma patients are treated with drugs called BRAF or MEK inhibitors that specifically target the mutant proteins created in cancerous tumors.  These inhibitors can block the tumors’ ability to grow and spread. According to Ann Richmond, Ingram Professor of Cancer Research and professor of pharmacology… Read More